None listed
Conditions
Brief summary
Gout is a chronic inflammatory arthritis. This study aims to see if krill oil ( a natural anti-inflammatory therapy) can reduce inflammation in people with gout, as well as the current standard of care, colchicine. People with gout, and evidence of inflammation on ultrasound will be randomized to either krill oil or colchicine for 12 weeks, and then return for a follow-up ultrasound to see if the ultrasound detected inflammation has decreased, increased or unchanged. WE will also look to see what effects krill oil has on pain, quality of life, global health, blood test of inflammation and the number of flares of gout.
Interventions
Krill oil 1gm twice daily for 12 weeks
oral capsule.
Pill count will be used to check compliance.
Sponsors
Royal Perth Hospital
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. A diagnosis of gout according to 2015 ACR criteria 21 2. Evidence of inflammation as defined as a CRP>5, or PD signal on US. 3. Able, and willing to commence either krill oil or colchicine. 4. Currently taking, or willing to commence allopurinol therapy. 5. Happy to consent to krill oil therapy for 12 weeks, and review at 12 weeks
Exclusion criteria
1. Use of anticoagulants or high dose aspirin (krill oil is contra–indicated in such people). 2. Unwillingness to stop taking krill oil and fish oil medications during the trial. 3. Other forms of inflammatory arthritis (especially rheumatoid arthritis and gout). 4. eGRF <50 5. Moderate to severe hepatic impairment 6. Seafood allergy. 7. Injections of corticosteroids (last 3 months) 8. Pregnancy or breastfeeding. 9. Presence of any serious medical illness that may preclude 12 week follow up. 10. Inability to provide informed consent
Outcome results
None listed